Azacitidine in lower-risk myelodysplastic syndromes

Leukemia Research

Volumn 33, Issue SUPPL. 2, 2009, Pages

  Santini, Valeria ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Azacitidine; DNA methylation; Low risk; Myelodysplastic syndromes Therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; VALPROIC ACID; ZEBULARINE;

ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; INFECTION; LOW RISK PATIENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; AZACITIDINE; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 71149101375     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(09)70230-9     Document Type: Article

References (19)

1. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
2. Kasner M.T., and Luger S.M. Update on the therapy for myelodysplastic syndrome. Am J Hematol 84 (2009) 177-186
3. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 25 (2007) 1908-1915
4. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25 (2007) 3503-3510
5. Lyons R.M., Cosgriff T.M., Modi S.S., Gersh R.H., Hainsworth J.D., Cohn A.L., et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27 (2009) 1850-1856
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes V.2.2010. Available at: http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf Accessed October 7, 2009.
7. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10 (2009) 223-232
8. Kornblith A.B., Herndon II J.E., Silverman L.R., Demakos E.P., Odchimar-Reissig R., Holland J.F., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20 (2002) 2441-2452
9. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20 (2002) 2429-2440
10. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Blackstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24 (2006) 3895-3903
11. Santini V., Gozzini A., Lunghi T., and Bosi A. Azacitidine in combination with EPO+G-CSF and valproic acid rapidly determines hematological improvement in pretreated non responsive IPSS INT-1 MDS patients. Leuk Res 31 Suppl 1 (2007) Abstract P151.
12. Musto P., Maurillo L., Spagnoli A., D'Arco A., Pollio B., Candoni A., et al. Azacitidine for the treatment of lower-risk myelodysplastic syndromes: final results from an Italian named patient program. Leuk Res 33 Suppl 1 (2009) Abstract P116.
13. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 (2006) 419-425
14. Mabaera R., Greene M.R., Richardson C.A., Conine S.J., Kozul C.D., and Lowrey C.H. Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin. Blood 111 (2008) 411-420
15. Christman J.K. 5-Azacytidine and 5-aza-2 -deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21 (2002) 5483-5495
16. Santini V. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. Expert Rev Hematol 2 (2009) 121-127
17. Jiang Y., Dunbar A., Gondek L.P., Mohan S., Rataul M., O'Keefe C., et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113 (2009) 1315-1325
18. Cortelezzi A., Colombo G., Pellegrini C., Silvestris I., Mazzeo L.M., Bosari S., et al. Bone marrow glycophorin-positive erythroid cells of myelodysplastic patients responding to high-dose rHuEPO therapy have a different gene expression pattern from those of nonresponders. Am J Hematol 83 (2008) 531-539
19. Flotho C., Claus R., Batz C., Schneider M., Sandrock I., Ihde S., et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23 (2009) 1019-1028